Abstract：
Nanozymes, which can selectively scavenge reactive oxygen species (ROS), have recently emerged as promising candidates for treating ischemic stroke and traumatic brain injury (TBI) in preclinical models. ROS overproduction during the early phase of these diseases leads to oxidative brain damage, which has been a major cause of mortality worldwide. However, the clinical application of ROS-scavenging enzymes is limited by their short in vivo half-life and inability to cross the blood-brain barrier. Nanozymes, which mimic the catalytic function of natural enzymes, have several advantages, including cost-effectiveness, high stability, and easy storage. These advantages render them superior to natural enzymes for disease diagnosis and therapeutic interventions. This review highlights recent advancements in nanozyme applications for ischemic stroke and TBI, emphasizing their potential to mitigate the detrimental effect of ROS overproduction, oxidative brain damage, inflammation, and blood-brain barrier compromise. Therefore, nanozymes represent a promising treatment modality for ROS overproduction conditions in future medical practices.
摘要：
纳米酶，可以选择性地清除活性氧（ROS），最近已成为临床前模型中治疗缺血性中风和创伤性脑损伤（TBI）的有希望的候选人。在这些疾病的早期阶段，ROS过量产生会导致氧化脑损伤，这一直是全世界死亡的主要原因。然而,ROS清除酶的临床应用受到其体内半衰期短和不能穿过血脑屏障的限制。纳米酶，模拟天然酶的催化功能，有几个优点，包括成本效益，高稳定性,和易于存储。这些优点使它们优于用于疾病诊断和治疗干预的天然酶。这篇综述强调了纳米酶在缺血性卒中和TBI中应用的最新进展。强调它们减轻ROS生产过剩的有害影响的潜力，氧化性脑损伤，炎症,和血脑屏障妥协。因此,纳米酶代表了未来医疗实践中ROS生产过剩条件的一种有希望的治疗方式。
